{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:49:36Z","timestamp":1787615376039,"version":"build-2736575974"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Inactivated Sinovac-CoronaVac vaccine (Sinovac Life Sciences, Beijing) for coronavirus disease 2019 (COVID-19) has been used in many countries. However, its immunogenicity profile in immunosuppressed dermatological patients is lacking. This prospective observational case-control study compared the humoral immune response between adult dermatological patients receiving systemic immunosuppressive therapies (<jats:italic>n<\/jats:italic> = 14) and those who did not (<jats:italic>n<\/jats:italic> = 18); excluding patients with HIV infection, cancer, non-dermatological autoimmune conditions, previous COVID-19 infection, and positive anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG prior to vaccination. The subjects were advised to withhold methotrexate for 1 week after each vaccine dose while continuing other therapies unadjusted. Anti-SARS-CoV-2 IgG antibody, surrogate neutralizing antibody (sNAb), and seroconversion rates (calculated from the percentages of participants in the group with positive sNAb) were used to assess immunogenicity. We found that participants using azathioprine, cyclosporin, mycophenolate mofetil, or prednisolone \u2265 10 mg\/day had a lower level of serum anti-SARS-CoV-2 IgG antibody and sNAb than those received methotrexate \u2264 10 mg\/week, prednisolone &amp;lt; 10 mg\/day, or biologics (i.e., secukinumab, ixekizumab, omalizumab). Patients who received methotrexate \u2264 10 mg\/week, prednisolone &amp;lt; 10 mg\/day or the biologics had a similar immunogenicity profile to those without immunosuppressive therapies. Despite the lack of statistical significance, a reduction of humoral immune response was observed among the study participants who used \u22652 immunosuppressants or pemphigus patients. Our findings suggest that a subset of patients with immune-mediated skin conditions respond poorly to the vaccine despite having low-level immunosuppression. These patients could benefit from vaccines that trigger a greater level of immunogenicity or booster doses.<\/jats:p>","DOI":"10.3389\/fmed.2021.769845","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T04:29:04Z","timestamp":1638937744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants"],"prefix":"10.3389","volume":"8","author":[{"given":"Chutima","family":"Seree-aphinan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumutnart","family":"Chanprapaph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploysyne","family":"Rattanakaemakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chavachol","family":"Setthaudom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanitta","family":"Suangtamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherrin","family":"Pomsoong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanisa","family":"Ratanapokasatit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonkiat","family":"Suchonwanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/HAB-200420","article-title":"Global burden of COVID-19: situational analysis and review","volume":"29","author":"Gebru","year":"2021","journal-title":"Hum Antibodies."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41591-021-01337-2","article-title":"COVID-19 dynamics after a national immunization program in Israel","volume":"27","author":"Rossman","year":"2021","journal-title":"Nat Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00296-021-04910-7","article-title":"Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly","volume":"41","author":"Seyahi","year":"2021","journal-title":"Rheumatol Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/art.41928","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1002\/jmv.26937","article-title":"Potential false-positive reasons for SARS-CoV-2 antibody testing and its solution","volume":"93","author":"Ye","year":"2021","journal-title":"J Med Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003901","article-title":"Clinical impact, reactogenicity, and immunogenicity after the first coronavac dose in kidney transplant recipients","author":"Medina-Pestana","year":"2021","journal-title":"Transplantation."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","volume":"17","author":"Karacin","year":"2021","journal-title":"Future Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.769845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T04:29:06Z","timestamp":1638937746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.769845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":13,"alternative-id":["10.3389\/fmed.2021.769845"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.769845","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"article-number":"769845"}}